Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5208741 | 0.84 | TSHR (0.32) | TSHRMAPT | |
| SCHEMBL2416243 | 0.84 | TSHR (0.32) | TSHRMAPT | |
| SCHEMBL2406517 | 0.82 | HCAR2 (0.43) | TSHR | |
| SCHEMBL5209514 | 0.79 | MAPT (0.33) | TSHRMAPT | |
| SCHEMBL18215276 | 0.75 | — | — | |
| SCHEMBL34386 | 0.75 | — | — | |
| SCHEMBL18215270 | 0.75 | — | — | |
| SCHEMBL510760 | 0.74 | HCAR2 (0.48) | TSHRMAPT | |
| SCHEMBL1062134 | 0.74 | HCAR2 (0.48) | TSHRMAPT | |
| SCHEMBL510759 | 0.74 | HCAR2 (0.48) | TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559716-B1 | PYRAZOLONAPHTHYRIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20100093782-A1 | Pyrazolonaphthyridine derivatives | KANAZAWA HASHIME | 2010-04-15 | — | — | US | disclosed |
| US-7608716-B2 | Pyrazolonaphthyridine derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-10-27 | — | — | US | disclosed |
| US-20060040972-A1 | Pyrazolonaphthyridine derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-23 | — | — | US | disclosed |
| EP-1559716-A1 | PYRAZOLONAPHTHYRIDINE DERIVATIVE | Grelan Pharmaceutical Co., Ltd. (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040972-A1 | Pyrazolonaphthyridine derivative | PDE3B, PDE3A, PDE4A | TSHR 1576/4885MAPT 4759/4885 |
| US-20100093782-A1 | Pyrazolonaphthyridine derivatives | PDE3B, PDE3A, PDE4A | TSHR 1639/4885MAPT 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.